Instituto Interamericano de Cooperación para la Agricultura | Resultados, nuestro compromiso

  •     Inter-American Institute for Cooperation
       on Agriculture
  •   Agriculture: A priority for sustainable
      development in the Americas
Willadsen, P. Kemp, D.H.

Pasado, presente y futuro de la vacunación contra garrapatas Control de resistencia en garrapatas y moscas de importancia veterinaria y enfermedades que transmiten - Puerto Vallarta, Jalisco (México) 1999 - p. 131-140

32 ref.

Two recombinant vaccines against the tick B. microplus have been available commercially for aproximately 5 years. These are the Australian vaccines sold as TickGARD and TickGARDPlus and the Cuban vaccine sold as Gavac and GavacPlus. Both rely on a single recombinant antigen, Bm86, in an adjuvant. Both vaccines are still making steady though relatively slow inroads intro the traditional market for acaricides. An increase in the use of vaccine and a concomitant decrease in the use of chemical acaricides are likely to come from three directions. The first will be the improvement in efficacy, either through achievement of a more sustained antibody response, or more probably through the incorporation of additional recombinant antigens. The number of potentially useful antigens continues to increase, though relatively slowly. Secondly, there is likely to be an extension of the vaccine to other tick species. Evidence is accumulating that such control of Boophilus annulatus using the B. microplus vaccine from four laboratories in different parts of the world. Thirdly, there is the unexplored potential for a reduction in chemical usage through the synergistic action of vaccines and chemical acaricide. Another area of potential enormous long-term benefit is in the control of tick-borne disease. The study of the complex of interactions between host, tick and transmitted parasite is producing some fascinating, though still preliminary results. The greatest constraint in the pratical application of much of this science is likely to come not from the science itself, but from the commercial imperatives which play a decisive role in registration and adoption